Comparison of Treatment Outcomes of Intravenous versus Intra-arterial Chemotherapy in Retinoblastoma
DOI:
https://doi.org/10.70749/ijbr.v3i9.2676Keywords:
Retinoblastoma, intravenous chemotherapy, ocular salvage, tumor regression, intra-arterial chemotherapyAbstract
Background: Retinoblastoma is the most common intraocular malignancy in children. While systemic intravenous chemotherapy (IVC) has improved outcomes, responses remain suboptimal in advanced disease. Intra-arterial chemotherapy (IAC) offers targeted drug delivery, but direct comparative evidence remains limited in resource-constrained settings. Objective: To compare treatment outcomes of IVC versus IAC in patients with retinoblastoma. Methods: A quasi-experimental study was conducted at the Department of Ophthalmology, Lahore General Hospital, from July 2024 to June 2025. Ninety-two children with newly diagnosed intraocular retinoblastoma (stages B-E) were randomized into two groups of 46 patients each. Group A received systemic IVC with vincristine, etoposide, and carboplatin. Group B received IAC with melphalan, with topotecan or carboplatin added for resistant disease. Tumor response was assessed according to WHO Response Evaluation Criteria. Data were analyzed using chi-square test with significance at p<0.05. Results: Overall treatment efficacy was achieved in 34 patients (73.9%) in the IAC group compared to 23 patients (50.0%) in the IVC group (p=0.018). Complete remission was significantly higher in the IAC group at 39.1% versus 15.2% (p=0.024). Progressive disease occurred in only 4.3% of IAC-treated patients compared to 17.4% of IVC-treated patients (p=0.019). Disease control was achieved in 73.9% of IAC patients versus 50.0% of IVC patients. Conclusion: Intra-arterial chemotherapy demonstrated superior efficacy compared to intravenous chemotherapy in managing advanced retinoblastoma. These findings support adoption of IAC as a preferred treatment modality in suitable cases to maximize tumor control and eye preservation.
Downloads
References
1. Kaew haw R, Rajanpur D. Retinoblastoma: etiology, modeling, and treatment. Cancers (Basel). 2020;12(8):2304.
https://doi.org/10.3390/cancers12082304
2. Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Boubacar SA, Ademola-Popoola DS, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020;6(5):685–695.
https://doi.org/10.1001/jamaoncol.2019.6716.
3. Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1339–1343.
https://doi.org/10.1001/archopht.1996.01100140539004.
4. Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68(11):2356–2365.
https://doi.org/10.4103/ijo.IJO_721_20.
5. Schaiquevich P, Fabius AW, Francis JH, Chantada GL, Abramson DH. Ocular pharmacology of chemotherapy for retinoblastoma. Retina. 2017;37(1):1–10.
https://doi.org/10.1097/IAE.0000000000001275.
6. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma: initial results. Ophthalmology. 2008;115(8):1398–1404.e1.
https://doi.org/10.1016/j.ophtha.2007.12.014.
7. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117(8):1623–1629.
https://doi.org/10.1016/j.ophtha.2009.12.030.
8. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118(10):2081–2087.
https://doi.org/10.1016/j.ophtha.2011.03.013.
9. Wyse E, Handa JT, Friedman AD, Pearl MS. A review of the literature for intra-arterial chemotherapy used to treat retinoblastoma. Pediatr Radiol. 2016;46(9):1223–1233.
https://doi.org/10.1007/s00247-016-3554-6.
10. Chen Q, Zhang B, Dong Y, Mo X, Zhang L, Huang W, et al. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC Cancer. 2018;18(1):486.
https://doi.org/10.1186/s12885-018-4406-6.
11. Abramson DH, Fabius AWM, Issa R, Francis JH, Marr BP, Dunkel IJ, et al. Advanced unilateral retinoblastoma: the impact of ophthalmic artery chemosurgery on enucleation rate and patient survival at MSKCC. PLoS One. 2015;10(12):e0145436.
https://doi.org/10.1371/journal.pone.0145436.
12. Venturi C, Bracco S, Cerase A, Cioni S, Galluzzi P, Gennari P, et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments. Acta Ophthalmol. 2013;91(4):335–342.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
